A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2029

Conditions

Respiratory Syncytial Viruses

Interventions

BIOLOGICAL

Prior standard of care receipt of Pfizer's ABRYSVO vaccine

Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.

Trial Locations (1)

Pfizer, New York